Consider treatment with the first and only FDA-approved drug for HRS in adults with rapid reduction in kidney function: TERLIVAZ® (terlipressin)
Terlipressin is recommended by AASLD Guidance and ACG guidelines
Demonstrated a significantly higher rate of verified HRS reversal, defined as improvement in renal function, avoidance of dialysis, and short-term survival
Treatment earlier in disease progression was associated with a higher rate of HRS reversal and lower rate of respiratory failure
Terlipressin can be used to treat patients outside of the ICU on the regular medical floor
The most commonly observed adverse reactions in patients treated with terlipressin were abdominal pain, nausea, respiratory failure, diarrhea, and dyspnea